Satelite Symposia

Sunday, 17 February

12:00 – 13:15 Seehorn

Satellite Symposium Boehringer Ingelheim (a lunch bag will be offered)

Empagliflozin: From Diabetes control to cardiovascular protection

Chairperson :
T. F. Lüscher, London

12:00 – 12:40

EMPA-REG® OUTCOME: Breakthrough in diabetes care

S. D. Anker, Berlin
12:40 – 13:15

EMPRISE® Program: Real-World Evidences on Empagliflozin efficacy, safety and costs

A. Karasik, Ramat Gan
18:00 – 19:15 Davos 2

Satellite Symposium Sanofi

ODYSSEY: Safe arrival of the flag ship for PCSK9 inhibition

S. Windecker, Berne

F. Mach, Geneva

18:00 – 18:25

Are we all hyperlipidemic? Urgency to treat

T. F. Lüscher, London
18:25 – 18:50

ODYSSEY OUTCOMES: What does a cardiologist need to know

P. G. Steg, Paris
18:50 – 19:15

Risk stratification in secondary prevention: Identification of the right patients for PCSK9 inhibition

B. Ference, Cambridge